SUPPLEMENTAL DIGITAL CONTENT (SDC)
. Summary of primary outcomes from the 11 included studies 5   Table S7 . Summary of secondary outcomes from the 11 included studies 8 Table S8 . Critical appraisal results for the 11 included studies using the Drummond checklist 
Jassal et al. 2003
Patient age (elderly>60), comorbidity, wait time, and type of dialysis (exclusive in-center HD)
3% both Utility of life quality after transplantation
Mendeloff et al. 2004
Cost of dialysis and in/after the first year of transplant; utility of life quality associated with dialysis and transplantation 3% both --(no sensitivity analyses were conducted to compare DDRT versus dialysis)
Whiting et al. 2004
Investment of donor initiative programs (Donor Action) 5% both Number of additional donors generated by Donor Action and time frame
Mutinga et al. 2005
Patient race and matching algorithm (eliminating HLA-B from allocation scheme) 5% both --(no sensitivity analyses were conducted to compare DDRT versus dialysis)
Quinn et al. 2007
Access to transplant (equal access for all age groups vs. eliminate access for patients with age>60) 5% both --(robust)
Dominguez et al. 2011
--8% both --(no sensitivity analyses were conducted)
Ong et al. 2015
Comorbidity (diabetes) 3% both --(no sensitivity analyses were conducted to compare DDRT vs. dialysis)
YaghoubiFard et al. 2016
Patient-borne cost (both patient's and hospital's perspective were analyzed) and type of dialysis (exclusive HD) 3% both --(robust)
Axelrod et al. 2018
Risk factor of deceased donor (risk based on KDPI and presence of viral diseases)
3% both --(robust)
ICES, incremental cost-effectiveness ratio; HD, hemodialysis; DALY, disability-adjusted life year; PD, peritoneal dialysis; HLA, Human Leukocyte Antigen; KDPI, Kidney Donor Profile Index. 
Was a comprehensive description of the competing alternatives given?
Was the effectiveness of the programme or services established?
Were all the important and relevant costs and consequences for each alternative identified?
Were costs measured accurately in appropriate physical units?
Were consequences measured accurately in appropriate physical units?
Were the cost valued credibly?
Were the consequences valued credibly?
Were costs adjusted for differential timing?
Were consequences adjusted for differential timing?
Was an incremental analysis of costs and consequences of alternatives done?
Was allowance made for uncertainty in the estimates of costs and consequences?
Did the presentation and discussion of study results include all issues of concern to users?
Total points (out of 10 points) 6.75 8.5 10 9.5 9. 
Only the first author's last name was shown in the first row. "P" represents "partial score" where half of the assigned weight (1 or 0.5) is included. Discussion of the appraisal results is presented on the next page. Low-risk studies have an average score between 0.9-1.0 (inclusive), medium-risks are between 0.7-0.9 (exclusive), and high-risk are those scored equal to or below 0.70.
SDC Discussion: Appraisal results using the Drummond checklist
Was a well-defined question posed in answerable form?
All the included studies had a clear research question in answerable form. Additionally, all of them assessed both the costs and the effects of deceased-donor renal transplant (DDRT) and dialysis, respectively. Most studies collapsed the dialysis category into one although there are different dialysis modalities (e.g., peritoneal dialysis, home hemodialysis, in-center hemodialysis and hemodialysis in a satellite unit). All studies clearly stated the perspective chosen in their analysis, of which 10 studies adopted a healthcare payer's perspective and one 10 assumed a patient's perspective.
For the purpose of this review, we strictly required that studies defined their patient population to be people with end-stage renal disease (ESRD) who are potential candidates for both DDRT and dialysis. This restriction implied that studies must explicitly state that they considered patients maintaining on dialysis who were either enlisted for a DDRT or were healthy enough to be considered a DDRT. Nine studies 2-7,9,11 specified the patient population accordingly. The remaining studies 1, 8, 10 that targeted the general dialysis vs. DDRT recipients are at risk of producing biased results since those on dialysis who are not awaiting a transplant are generally expected to use health care differently and are sicker than their listed counterparts. This creates heterogeneity between patient populations. Furthermore, one study did not specify the time horizon of their analysis. 4 Nevertheless, we did not attempt to pool the data across studies.
We noted that 6 studies 1,3,8,10,11 investigated the cost-effectiveness of DDRT over dialysis as their main research objective.
Was a comprehensive description of the competing alternatives given?
All studies acknowledged dialysis as a comparator of DDRT. Three 3,9,10 further defined the type of dialysis examined to be hemodialysis 9 or in-center hemodialysis 3, 10 we focused on studies that compared DDRT and dialysis. As stated previously not all alternatives for dialysis and a kidney transplant were provided in most studies.
Was the effectiveness of the programme or services established?
Due to the infeasibility of randomized controlled clinical trials in the current context, all of the included studies relied on observational data to inform effectiveness estimation. Five studies 1,6,9-11 established effectiveness by using person-level deidentified administrative record, including those retrieved from the United States Renal Data System (USRDS) 6, 11 , the Scientific Registry of Transplant Recipient (SRTR) 11 , as well as clinical data housed at national or hospital 
Were all the important and relevant costs and consequences for each alternative identified?
One study 10 included patient-borne costs of dialysis and DDRT, including the tariffs paid by patients and the costs of travel, accommodation, and loss of salary due to work absence. The remaining 10 studies 1-9,11 all took a health payer's perspective and thus identified only the direct medical cost associated with dialysis and DDRT. These studies may be subjected to bias due to neglecting payments made by patients or their families.
Two studies 2,7 did not provide sufficient explanations to the cost components in their analysis by using lump sum cost estimates for DDRT under just 3 categories: nephrectomy (surgery), year on, and follow-up after year 1. Furthermore, while the majority of studies acknowledged a higher transplant cost during the first postoperative year and lower costs for maintenance phase thereafter, one study 10 failed to recognize this pattern, making it to be at risk of overestimating the total transplant cost. Costs associated with transplant workup (including organ procurement) and graft failure (including nephrectomy and dialysis reinitiation fee) were not investigated by 6 studies 1,2,7,9-11 and 5 studies 1,2,4,7,10 , respectively, who were likely to produce biased results that favoured transplantation by underestimating the total transplant costs.
5a. Were costs measured accurately in appropriate physical units?
Most studies measured each cost component by multiplying the unit cost to the quantity of resource used. One study 10 did not provide any unit cost estimate but used a lump-sum estimate for the total cost of transplant and dialysis, respectively. The same study also relied entirely on hospital payment record and patient interviews to arrive at their cost estimations, which lacks accuracy given the small sample of patients examined (32 dialysis recipients and 29 DDRT recipients).
5b. Were consequences measured accurately in appropriate physical units?
Quality-adjusted life-years (QALY) were used in the majority of the studies, 2-9,11 followed by life-years (LY) 3, 7 and disability-adjusted life-years (DALY). 1, 10 Two studies 3,7 evaluated both QALY and LY, but did not report discounted LYs. QALYs were computed by multiplying the number of LYs in 1 health state by the corresponding utility measures that were obtained from published literature. DALYs were calculated as the sum of years of life loss (YLLs) and years lived with disability (YLDs). The disability weight was estimated based on a questionnaire emailed to 95 healthcare officials in a Japanese study 1 and results of a published study in an Iranian study, 10 both of which were credible sources.
6a. Were the cost valued credibly?
All costs were valued in monetary units. US Dollars were the most common currency (used by 6 studies 3,4,6,8,10,11 ), followed by a variety of international currencies (including Canadian Dollars, 5, 7 Japanese Yen, 1 Singapore Dollars, 9 and Euros 2 ). All studies identified the year of their currency. Costs were constructed by microcosting methods using actual person-level healthcare utilization data extracted from well-validated administrative databases, including Medicare of the US. 6, 11 Three studies used patients files provided by hospital 1, 10 or other national insurance database. 9 The remaining studies [2] [3] [4] [5] 7, 8 derived cost data using governmental reports (on medical procedure prices) and previous literature. One study 10 that considered patient payments for dialysis and DDRT obtained cost estimates by interviewing patients and their families.
One study 1 used the total national expenditure for dialysis and the proportion of inpatient dialysis to estimate individual dialysis cost, but did not specify how they calculated the annual cost after transplantation. Another study 10 did not provide aby explanation on the type of hospital costs evaluated for patients in their cohort.
6b. Were the consequences valued credibly?
Outcomes were measured in LYs in all papers and then adjusted to QALYs 2-9,11 or DALYs 1,10 in some occasions. Five studies 1,6,9-11 established LYs using person-level data (eg, survival time after DDRT) in conjunction with appropriate statistical analysis (eg, survival curve).
The remaining studies [2] [3] [4] [5] 7, 8 relied entirely on published data for LYs. For utility, all studies used previous literature with proper justifications of their choice.
7a. Were costs adjusted for differential timing?
All studies applied discounting to costs. A wide range of annual discount rates was used, including 3%, 1,3,4,9-11 5%, 2,5-7 and as high as 8%. 
7b. Were consequences adjusted for differential timing?
All studies applied discounting to future effects with proper justifications of the chosen discount rate.
Was an incremental analysis of costs and consequences of alternatives done?
For the purpose of this review, we strictly defined incremental analysis to consist of a computation of an incremental cost-effectiveness ratio (ICER) that compared DDRT and dialysis.
Cost-effectiveness (or cost-utility) ratios (CERs or CURs or average CER or average CUR) that estimated the unit cost per outcome gained by DDRT or dialysis were not accepted as an incremental measure. Calculation of ICER was unnecessary for 5 studies 1,2,5,7,8 that concluded DDRT to dominate dialysis under all conditions. For the rest of the 6 studies, only 2 3,4 reported
ICERs that were computed correctly. One study 9 wrongly claimed dialysis to dominate DDRT when DDRT was demonstrated to be more expensive but also more effective at producing QALYs.
Another study 10 reported ICERs that were incorrectly computed, given their reported total respective costs and effects of DDRT and dialysis. Two studies 6, 11 only reported the CURs of DDRT and dialysis so we calculated an ICER based on their estimates of the incremental cost/effect.
Was allowance made for uncertainty in the estimates of costs and consequences?
All but one study 8 performed sensitivity analyses to assess the robustness of their main results. Specifically, 8 studies 1-3,5-7,9,10 performed a 1-way sensitivity analysis that varied parameter inputs 1 at a time to identify significant modifiers of the main results. Since a high/low value must be assigned to each parameter in a 1-way sensitivity analysis, 5 studies 1-3,7,9 obtained their high/low estimates from previous literature, and 2 6,9 varied each base-case input value by some percentages (eg, up and down by 30%). Two studies 1, 5 only assessed a limited number of parameters in the 1-ways sensitivity analysis and made no effort to verify if other parameters were also be impactful.
Another study 10 did not present the low/high value for any parameter examined in their 1-way sensitivity analysis.
Furthermore, one study 11 performed extensive probabilistic sensitivity analyses in which all parameter inputs were varied simultaneously, each drawn from a predetermined statistical distribution with abundant justifications of the choice. Another study 4 conducted a series of sensitivity and scenario analysis that was not typical in economic evaluations (ie, not in the form of 1-way, 2-way, or probabilistic sensitivity analyses). However, through their extensive search in the literature and appropriate use of statistical techniques we agree that the robustness of their findings was established.
Did the presentation and discussion of study results include all issues of concern to users?
All studies have clearly stated the cost-effectiveness results based on the ICERs or CERs (or CURs) obtained from the analysis. One study 10 concluded DDRT to be more costly than dialysis but was still cost-effective without providing a willingness-to-pay threshold.
Eleven studies discussed their main findings in comparison with the results of prior literature. One early study 1 that possibly represents the first cost-effectiveness analysis of DDRT vs. dialysis in the respective country (Japan) has limited ability to contrast their study findings with others.
Generalizability was discussed by 8 studies 3-7,9-11 who gave extensive discussions on the limitation of their analysis, especially on the heterogenous nature of data sources used to derive parameter inputs. Two studies 1, 8 did not discuss the potential limitations of their analysis at all, and one 2 only briefly mentioned 2 weaknesses of their analysis while neglecting other important limitations that were potentially important.
Finally, all studies have provided in-depth discussion on the policy implications in public health, including allocations and access of DDRT, 1, 6, 7, 10 N/A Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
2-3
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
2 Search 8 Present full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. Table S1 -S5 Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
5
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 5
Risk of bias in individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. Table  S8 Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 6
5-6;
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis. Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
6; Table S8 Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, metaregression), if done, indicating which were prespecified.
N/A

RESULTS
Study selection
17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
6; Figure 2 Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Table S8 Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
12-13
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
14-15
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
13-14
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. For more information, visit: www.prisma-statement.org.
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